International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC publication no. 6: do treatments available for psoriasis patients carry a genetic or carcinogenic risk?
D000875:Anthralin / Q000494:pharmacology; D001379:Azathioprine / Q000494:pharmacology; D002273:Carcinogens; D003033:Coal Tar / Q000494:pharmacology; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D009152:Mutagenicity Tests; D009153:Mutagens; D009154:Mutation; D011701:PUVA Therapy; D011336:Probability; D011565:Psoriasis / Q000188:drug therapy*; D012306:Risk; D012486:Salmonella typhimurium / Q000235:genetics
D002273:Carcinogens; D009153:Mutagens; D003033:Coal Tar; D001379:Azathioprine; D000875:Anthralin; D006918:Hydroxyurea; D008727:Methotrexate